• HOME
  • ABOUT US+
    • CAREERS
  • SPECIALTIES+
    • Rheumatology
    • Gastroenterologists
    • Neurologists
    • Pulmonology, Allergy and ENT
  • SERVICES+
    • Billing and Reimbursement Solutions
    • Buy and Bill Education
    • Clinical Staffing & training Services
    • Compliance & Regulatory Guidance
    • In-Office Infusion Suite Setup
    • Patient Access & Financial Assistance Services
    • Specialty Medication Coordination & Procurement
    • Specialty Program Implementation
    • Technology & Workflow Optimization for Infusion Therapy
  • BLOG+
  • EVENTS
  • CONTACT US
Maximizing Efficiency and Patient Outcomes Through In-Office Infusion Programs

Maximizing Efficiency and Patient Outcomes Through In-Office Infusion Programs

Flu Season and Biologics: What Patients with Multiple Sclerosis Should Know

Flu Season and Biologics: What Patients with Multiple Sclerosis Should Know

When Coverage Disappears: The Hidden Risks of Alternative Funding Programs for Patients on Biologics

When Coverage Disappears: The Hidden Risks of Alternative Funding Programs for Patients on Biologics

Managing Morning Stiffness: How Biologics Support Daily Life for Rheumatoid Arthritis Patients

Managing Morning Stiffness: How Biologics Support Daily Life for Rheumatoid Arthritis Patients

The 340B Rebate Controversy: What Providers Need to Know About Drugmaker Pushback

The 340B Rebate Controversy: What Providers Need to Know About Drugmaker Pushback

Fall Allergies or Something More? Understanding Chronic Sinusitis and Biologic Treatment Options

Fall Allergies or Something More?

Relieving the Bottleneck: Helping Providers Accelerate Patient Access to Biologic Therapies

Relieving the Bottleneck: Helping Providers Accelerate Patient Access to Biologic Therapies

Flare-Proof Fall: Managing Autoimmune Conditions as Temperatures Drop

Flare-Proof Fall: Managing Autoimmune Conditions as Temperatures Drop

A quiet but significant change is coming to the 340B Program, and it could reshape the way your practice manages high-cost specialty drugs. Starting in 2026, the Department of Health and Human Services (HHS) will test a new Rebate Model Pilot that lets drug manufacturers offer rebates instead of the traditional upfront discounts on certain 340B drugs. At first glance, this might sound like a technical policy shift. However, for specialty practices like yours, it could mean new financial pressures, administrative headaches, and cash flow challenges. Let’s break down what’s changing, why it matters, and how you can prepare.

The 340B Rebate Pilot Is Coming: What Providers Need to Know About the Shift from Discounts to Rebates

Biologics and the Bottom Line: Understanding Your Real Costs — and How to Manage Them

Biologics and the Bottom Line: Understanding Your Real Costs

1 2 3 4 … 35 Next

Subscribe For Newsletter

Error: Contact form not found.

Altus Biologics delivers comprehensive in-office biologic therapy solutions tailored to specialty practices. Subscribe to our newsletter today.

Altus Biologics delivers comprehensive in-office infusion and biologic therapy solutions tailored to specialty practices.

11233 Shadow Creek Parkway, Suite 303, Pearland, TX 77584, USA
info@altusbiologics.com
+1 855.692.5887

Quick Link

  • Optimizing In-Office Biologics Therapy Solutions
  • Careers
  • Services
  • Contact
  • Blog

Recent Post

Maximizing Efficiency and Patient Outcomes Through In-Office Infusion Programs

Maximizing Efficiency and Patient Outcomes Through In-Office Infusion Programs

1 week ago
Flu Season and Biologics: What Patients with Multiple Sclerosis Should Know

Flu Season and Biologics: What Patients with Multiple Sclerosis Should Know

3 weeks ago
11233 Shadow Creek Parkway, Suite 303, Pearland, TX 77584, USA
info@altusbiologics.com
+1 855.692.5887

Copyright 2025 Altus Biologics All Rights Reserved.

Facebook
X
Instagram
LinkedIn